Prescription stimulant consumption in the United States compared with 35 other countries
Clicks: 1
ID: 315313
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #58 of 91 articles by views in Health Affairs Scholar
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Previous studies have identified the US as a global outlier in stimulant prescribing. Given that stimulant prescribing in the US has continued to increase, we aimed to provide current international comparisons. Methods We analyzed 2024 stimulant consumption data from the International Narcotics Control Board, reported as defined daily doses for statistical purposes (S-DDD) per 1000 population per day. We compared the US with 35 Organization for Economic Cooperation and Development members. Results Overall, the US comprised 26.8% of the population and consumed 67.6% of prescription stimulants. Per 1000 population per day, the US had the second highest prescription stimulant consumption after Iceland. The volume of prescription stimulants consumed in the US per 1000 population per day was 569% of the mean of comparison countries. Further, only 31.2% of consumed prescription stimulants in the US was methylphenidate, versus 88.8% in comparison countries. Conclusion Additional research is needed on the clinical and public health consequences of these major differences in controlled substance policy and clinical practice between the US and other countries. For example, findings suggest a need to better understand any differential addictive potential of prescription stimulant regimens.
| Reference Key |
openalex_W7162792390
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Marcus A. Bachhuber, Ashly E. Jordan, Brian J. Piper |
| Journal | Health Affairs Scholar |
| Year | 2026 |
| DOI |
10.1093/haschl/qxag133
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.